Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Inoculum

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Inoculum. Displaying page 1 of 1.
    EudraCT Number: 2011-005929-49 Sponsor Protocol Number: VX11-787-101 Start Date*: 2012-02-20
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus
    Medical condition: Influenza A
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001107-20 Sponsor Protocol Number: MDT-637-CP-201 Start Date*: 2013-08-02
    Sponsor Name:MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd.
    Full Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b)
    Medical condition: RSV Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000643-27 Sponsor Protocol Number: VAC071 Start Date*: 2019-09-23
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: A Phase IIa challenge study to assess efficacy of the Plasmodium vivax malaria vaccine candidates ChAd63 PvDBP and MVA PvDBP in healthy adults living in the UK
    Medical condition: Plasmodium vivax malaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10047665 Vivax malaria (benign tertian) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-001841-11 Sponsor Protocol Number: MPOH06 Start Date*: 2021-11-09
    Sponsor Name:MaaT Pharma
    Full Title: Evaluation of the efficacy of MaaT013 as salvage therapy in acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial
    Medical condition: Salvage therapy of acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005510-34 Sponsor Protocol Number: MMV_DSM265_14_01 Start Date*: 2015-09-30
    Sponsor Name:Medicines for Malaria Venture
    Full Title: Evaluation of the prophylactic antimalarial activity of a single dose of DSM265 in non-immune healthy adult volunteers by controlled human malaria infection with PfSPZ Challenge
    Medical condition: Healthy volunteers; controlled human malaria infection with PfSPZ
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10025494 Malaria prophylaxis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002848-22 Sponsor Protocol Number: MV-004 Start Date*: 2020-12-03
    Sponsor Name:Meissa Vaccines Inc.
    Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Prophylactic Efficacy of MV-012-968 Against Respiratory Syncytial Virus (RSV) Infection in the Virus Challe...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-000854-73 Sponsor Protocol Number: TCN‐032‐002 Start Date*: 2012-06-21
    Sponsor Name:THERACLONE SCIENCES, INC.
    Full Title: A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TCN-032 (HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE M2 PROTEIN OF INFLUENZA A VIRUS) IN SUBJECTS CHALLENGED WITH H3N2 INFLUENZA A VIRUS
    Medical condition: Treatment of severe influenza A virus disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10070215 Influenza A virus test positive PT
    14.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Nov 29 20:59:48 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA